23:34 , Jun 15, 2017 |  BC Innovations  |  Tools & Techniques

Breaking the barrier

A three-way deal between Amgen Inc., Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a small...
02:36 , Mar 3, 2017 |  BC Week In Review  |  Clinical News

NA-1: Ph III ESCAPE-NA-1 started

NoNo began the double-blind, placebo-controlled, international Phase III ESCAPE-NA-1 trial to evaluate 2.6 mg/kg IV NA-1 in about 1,120 patients who are candidates for endovascular revascularization. NoNo Inc., Toronto, Ontario  Product: NA-1  Business: Neurology  Molecular target: Discs large homolog...
08:00 , Jan 7, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Mouse model of intellectual disability involving non-POU domain containing octamer-binding (NONO; NMT55) mutations

Disease modelsGABA A receptorGABRA2gephyrin (GPHN)non-POU domain containing octamer-bindingNMT55University of Zurich...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Clinical News

Patrys preclinical data

In vitro, PAT-LM1 induced cell death in mantle cell lymphoma (MCL) and histiocytic lymphoma cells. Patrys declined to disclose when it plans to start Phase I testing with the human IgM antibody that binds...
08:00 , Jan 20, 2014 |  BioCentury  |  Emerging Company Profile

Zocere: Stepping up in stroke

Zocere Inc. may have found a new way to decrease ischemic brain injury in patients following stroke. The company is developing an injectable, degradation-resistant version of the neuroprotective STEP protein that could improve patient outcomes...
07:00 , Apr 29, 2013 |  BioCentury  |  Emerging Company Profile

Avilex: One-two pain punch

Avilex Pharma ApS may have found a way to block activation of the NMDA receptor pathway to treat chronic pain and ischemic stroke. Rather than directly hitting the receptor itself, the approach targets a downstream...
07:00 , Mar 22, 2012 |  BC Innovations  |  Tools & Techniques

Monkeys bridge the stroke gap

Toronto-based NoNO Inc. has become the first company to show that macaque models have the potential to derisk clinical testing of new stroke therapies, which typically have gone right from rat or rabbit models into...
08:00 , Mar 8, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Neuroprotection and functional recovery in macaque models of stroke Macaque models could aid the development of neuroprotective therapies...
08:00 , Feb 8, 2010 |  BC Week In Review  |  Company News

CSL, Patrys deal

Patrys granted CSL an exclusive, worldwide license to develop products based on two undisclosed antibodies and an exclusive option to select up to two additional early-stage antibodies. Patrys will receive an undisclosed upfront fee and...
07:00 , Sep 10, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Stroke; nerve damage ...